摘要
目的:研究趋化因子受体CXCR7与细胞增殖指数Ki67在前列腺癌组织及良性前列腺增生组织中的表达水平及相关性。方法:应用免疫组织化学检测83例前列腺癌组织及40例良性前列腺增生组织中CXCR7与Ki-67的表达。结果:CXCR7和Ki67在前列腺癌标本中的阳性表达率分别为61.4%和69.9%,在良性前列腺增生组织中的表达率分别为17.5%和10.0%,CXCR7和Ki-67在前列腺癌组织中的表达呈正相关,差异具有统计学意义(P<0.05)。结论:CXCR7可能参与了细胞周期的调控,促进前列腺癌的发生、发展,对前列腺癌的诊断和治疗具有指导意义。
Objective:To study the CXCR7 and Ki67 expression and their correlation of them in prostatic cancer. Methods:The expression of CXCR7 and Ki67 was detected in 83 cases with prostatic cancer and in 40 cases with benign prostatic hyperplasia by the immunohistochemistry. Results:CXCR7 and Ki67 expression in the cases with prostatic cancer were 61.4% (51/83) and 69.9% (58/83), which were obviously higher than those in the cases with benign prostatic hyper-plasia 17.5% (7/40) and 10% (4/40) (P〈0.05).The expression of CXCR7 and Ki67 were coincident in prostatic cancer (P〈0.05). Conclusions:CXCR7 might take part in cell cycle control, so as to promote the occurrence and development of prostate cancer, and could have the guiding significance in its diagnosis and treatment of it.
出处
《交通医学》
2014年第5期445-448,共4页
Medical Journal of Communications